SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Nabi (NABI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Xpiderman who wrote (60)2/25/1997 7:03:00 PM
From: The BayWatcher   of 354
 
There are now 10 analysts covering NABI. 5

analysts have a strong buy, 4 have a moderate buy

and 1 has a hold. The increasing number of

analysts should help NABI's exposure and

consequently its share price. Also, I looked up

the curent P/Es for NABI's peers and most are

betwwen 60-90, including Biogen, Genentech, Chiron,


and Bio Technology General. NABI's current P/E is

26 and change. Given NABI's growth of 20% plus the

huge tax benefits coming that will further reduce

its P/E ratio, I can't see how the share price

isn't headed to 20 and beyond. This doesn't even

factor in forthcoming FDA approvals in 1997 and

1998. Once word of NABI spreads, the stock may

take off like that of BTGC in the past 6 months.

Please tell me if anyone thinks I am being too

optimistic or gullible.



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News